Compare ASMB & PSFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | PSFE |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.6M | 455.1M |
| IPO Year | 2010 | N/A |
| Metric | ASMB | PSFE |
|---|---|---|
| Price | $36.12 | $8.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $43.40 | $10.60 |
| AVG Volume (30 Days) | 131.0K | ★ 680.0K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $37,191,000.00 | ★ $1,683,103,000.00 |
| Revenue This Year | $42.01 | $1.95 |
| Revenue Next Year | N/A | $6.21 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.30 | N/A |
| 52 Week Low | $7.75 | $6.43 |
| 52 Week High | $39.71 | $24.11 |
| Indicator | ASMB | PSFE |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 48.86 |
| Support Level | $35.05 | $7.79 |
| Resistance Level | $38.82 | $8.65 |
| Average True Range (ATR) | 1.91 | 0.39 |
| MACD | -0.32 | 0.27 |
| Stochastic Oscillator | 42.70 | 92.78 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.